Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients

A retrospective collaborative survey from Italian hematology centers

Silvia Cantoni, Monica Carpenedo, Maria Gabriella Mazzucconi, Valerio De Stefano, Valentina Carrai, Marco Ruggeri, Giorgina Specchia, Nicola Vianelli, Fabrizio Pane, Ugo Consoli, Andrea Artoni, Francesco Zaja, Mariella D'adda, Andrea Visentin, Felicetto Ferrara, Wilma Barcellini, Domenica Caramazza, Erminia Baldacci, Elena Rossi, Alessandra Ricco & 4 others Angela Ciminello, Francesco Rodeghiero, Michele Nichelatti, Roberto Cairoli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65% achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8% of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80% of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4%. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.

Original languageEnglish
Pages (from-to)58-64
Number of pages7
JournalAmerican Journal of Hematology
Volume93
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Thrombopoietin Receptors
Idiopathic Thrombocytopenic Purpura
Hematology
Blood Platelets
Inosine Triphosphate
Patient Preference
Surveys and Questionnaires

ASJC Scopus subject areas

  • Hematology

Cite this

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients : A retrospective collaborative survey from Italian hematology centers. / Cantoni, Silvia; Carpenedo, Monica; Mazzucconi, Maria Gabriella; De Stefano, Valerio; Carrai, Valentina; Ruggeri, Marco; Specchia, Giorgina; Vianelli, Nicola; Pane, Fabrizio; Consoli, Ugo; Artoni, Andrea; Zaja, Francesco; D'adda, Mariella; Visentin, Andrea; Ferrara, Felicetto; Barcellini, Wilma; Caramazza, Domenica; Baldacci, Erminia; Rossi, Elena; Ricco, Alessandra; Ciminello, Angela; Rodeghiero, Francesco; Nichelatti, Michele; Cairoli, Roberto.

In: American Journal of Hematology, Vol. 93, No. 1, 01.01.2018, p. 58-64.

Research output: Contribution to journalArticle

Cantoni, S, Carpenedo, M, Mazzucconi, MG, De Stefano, V, Carrai, V, Ruggeri, M, Specchia, G, Vianelli, N, Pane, F, Consoli, U, Artoni, A, Zaja, F, D'adda, M, Visentin, A, Ferrara, F, Barcellini, W, Caramazza, D, Baldacci, E, Rossi, E, Ricco, A, Ciminello, A, Rodeghiero, F, Nichelatti, M & Cairoli, R 2018, 'Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers', American Journal of Hematology, vol. 93, no. 1, pp. 58-64. https://doi.org/10.1002/ajh.24935
Cantoni, Silvia ; Carpenedo, Monica ; Mazzucconi, Maria Gabriella ; De Stefano, Valerio ; Carrai, Valentina ; Ruggeri, Marco ; Specchia, Giorgina ; Vianelli, Nicola ; Pane, Fabrizio ; Consoli, Ugo ; Artoni, Andrea ; Zaja, Francesco ; D'adda, Mariella ; Visentin, Andrea ; Ferrara, Felicetto ; Barcellini, Wilma ; Caramazza, Domenica ; Baldacci, Erminia ; Rossi, Elena ; Ricco, Alessandra ; Ciminello, Angela ; Rodeghiero, Francesco ; Nichelatti, Michele ; Cairoli, Roberto. / Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients : A retrospective collaborative survey from Italian hematology centers. In: American Journal of Hematology. 2018 ; Vol. 93, No. 1. pp. 58-64.
@article{f147e066c96c44f1ad0795c8b5f04516,
title = "Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers",
abstract = "Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65{\%} achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8{\%} of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80{\%} of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4{\%}. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.",
author = "Silvia Cantoni and Monica Carpenedo and Mazzucconi, {Maria Gabriella} and {De Stefano}, Valerio and Valentina Carrai and Marco Ruggeri and Giorgina Specchia and Nicola Vianelli and Fabrizio Pane and Ugo Consoli and Andrea Artoni and Francesco Zaja and Mariella D'adda and Andrea Visentin and Felicetto Ferrara and Wilma Barcellini and Domenica Caramazza and Erminia Baldacci and Elena Rossi and Alessandra Ricco and Angela Ciminello and Francesco Rodeghiero and Michele Nichelatti and Roberto Cairoli",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ajh.24935",
language = "English",
volume = "93",
pages = "58--64",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients

T2 - A retrospective collaborative survey from Italian hematology centers

AU - Cantoni, Silvia

AU - Carpenedo, Monica

AU - Mazzucconi, Maria Gabriella

AU - De Stefano, Valerio

AU - Carrai, Valentina

AU - Ruggeri, Marco

AU - Specchia, Giorgina

AU - Vianelli, Nicola

AU - Pane, Fabrizio

AU - Consoli, Ugo

AU - Artoni, Andrea

AU - Zaja, Francesco

AU - D'adda, Mariella

AU - Visentin, Andrea

AU - Ferrara, Felicetto

AU - Barcellini, Wilma

AU - Caramazza, Domenica

AU - Baldacci, Erminia

AU - Rossi, Elena

AU - Ricco, Alessandra

AU - Ciminello, Angela

AU - Rodeghiero, Francesco

AU - Nichelatti, Michele

AU - Cairoli, Roberto

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65% achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8% of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80% of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4%. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.

AB - Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65% achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8% of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80% of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4%. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.

UR - http://www.scopus.com/inward/record.url?scp=85033465178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033465178&partnerID=8YFLogxK

U2 - 10.1002/ajh.24935

DO - 10.1002/ajh.24935

M3 - Article

VL - 93

SP - 58

EP - 64

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -